Tags

Type your tag names separated by a space and hit enter

An evaluation of baricitinib as a therapeutic option for adult patients with moderate to severe atopic dermatitis.
Expert Opin Pharmacother. 2020 Jun; 21(9):1027-1033.EO

Abstract

INTRODUCTION

Moderate-to-severe AD burdens a large proportion of AD patients and may represent an inadequacy of treatment options available for resistant disease.

AREAS COVERED

This review provides an overview of the therapies for moderate-to-severe AD in late-stage development and in the clinic, and focuses on baricitinib as an emerging therapeutic option. Baricitinib is an orally available selective JAK1/JAK2 inhibitor that is approved for use in the treatment of moderate-to-severe rheumatoid arthritis (RA). Baricitinib decreases AD lesions, disease severity, and improves quality of life. Overall, the small molecule inhibitor is well tolerated. However, its black-box warnings in the RA population raise a concern for its long-term safety.

EXPERT OPINION

Baricitinib is a promising treatment modality for moderate-to-severe AD. Its primary advantage over dupilumab, the revolutionary biologic agent approved for AD, is that patients prefer an oral medication over an injection. However, providers will likely prescribe an injectable over an oral medication if baricitinib has an unfavorable safety profile. Insurance coverage of baricitinib will also have a major role in clinical use. Baricitinib will likely face competition from other JAK inhibitors in the future; however, it will have an advantage if it becomes the first FDA-approved medication of its kind for resistant AD.

Authors+Show Affiliations

Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine , Winston-Salem, North Carolina.Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine , Winston-Salem, North Carolina.Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine , Winston-Salem, North Carolina.Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine , Winston-Salem, North Carolina. Department of Pathology, Wake Forest School of Medicine , Winston-Salem, NC, USA. Department of Social Sciences & Health Policy, Wake Forest School of Medicine , Winston-Salem, NC, USA. Department of Dermatology, University of Southern Denmark , Odense, Denmark.

Pub Type(s)

Journal Article
Multicenter Study
Review

Language

eng

PubMed ID

32208940

Citation

Mendes, Jocelyn T., et al. "An Evaluation of Baricitinib as a Therapeutic Option for Adult Patients With Moderate to Severe Atopic Dermatitis." Expert Opinion On Pharmacotherapy, vol. 21, no. 9, 2020, pp. 1027-1033.
Mendes JT, Balogh EA, Strowd LC, et al. An evaluation of baricitinib as a therapeutic option for adult patients with moderate to severe atopic dermatitis. Expert Opin Pharmacother. 2020;21(9):1027-1033.
Mendes, J. T., Balogh, E. A., Strowd, L. C., & Feldman, S. R. (2020). An evaluation of baricitinib as a therapeutic option for adult patients with moderate to severe atopic dermatitis. Expert Opinion On Pharmacotherapy, 21(9), 1027-1033. https://doi.org/10.1080/14656566.2020.1739268
Mendes JT, et al. An Evaluation of Baricitinib as a Therapeutic Option for Adult Patients With Moderate to Severe Atopic Dermatitis. Expert Opin Pharmacother. 2020;21(9):1027-1033. PubMed PMID: 32208940.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - An evaluation of baricitinib as a therapeutic option for adult patients with moderate to severe atopic dermatitis. AU - Mendes,Jocelyn T, AU - Balogh,Esther A, AU - Strowd,Lindsay C, AU - Feldman,Steven R, Y1 - 2020/03/25/ PY - 2020/3/27/pubmed PY - 2020/7/28/medline PY - 2020/3/27/entrez KW - Atopic dermatitis; baricitinib; eczema KW - JAK inhibitor KW - small molecule inhibitor KW - systemic agent SP - 1027 EP - 1033 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 21 IS - 9 N2 - INTRODUCTION: Moderate-to-severe AD burdens a large proportion of AD patients and may represent an inadequacy of treatment options available for resistant disease. AREAS COVERED: This review provides an overview of the therapies for moderate-to-severe AD in late-stage development and in the clinic, and focuses on baricitinib as an emerging therapeutic option. Baricitinib is an orally available selective JAK1/JAK2 inhibitor that is approved for use in the treatment of moderate-to-severe rheumatoid arthritis (RA). Baricitinib decreases AD lesions, disease severity, and improves quality of life. Overall, the small molecule inhibitor is well tolerated. However, its black-box warnings in the RA population raise a concern for its long-term safety. EXPERT OPINION: Baricitinib is a promising treatment modality for moderate-to-severe AD. Its primary advantage over dupilumab, the revolutionary biologic agent approved for AD, is that patients prefer an oral medication over an injection. However, providers will likely prescribe an injectable over an oral medication if baricitinib has an unfavorable safety profile. Insurance coverage of baricitinib will also have a major role in clinical use. Baricitinib will likely face competition from other JAK inhibitors in the future; however, it will have an advantage if it becomes the first FDA-approved medication of its kind for resistant AD. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/32208940/An_evaluation_of_baricitinib_as_a_therapeutic_option_for_adult_patients_with_moderate_to_severe_atopic_dermatitis_ L2 - https://www.tandfonline.com/doi/full/10.1080/14656566.2020.1739268 DB - PRIME DP - Unbound Medicine ER -